The Association for the Accreditation of Human Research Protection Programs Inc. (AAHRPP) has awarded accreditation to Pfizer Inc., strengthening research protections for hundreds of thousands of participants around the globe.
Pfizer is one of three organizations whose accreditation was approved by the AAHRPP Council on Accreditation in March. Others include a healthcare network in Connecticut and an independent institutional review board in Maryland.
The newly accredited organizations are:
· Hartford HealthCare, Hartford, Conn.
· MaGil IRB Inc., Rockville, Md.
· Pfizer Inc., New York, N.Y.
The accreditation of Pfizer—the world’s largest research-based pharmaceutical company and the first major commercial research sponsor to attain AAHRPP accreditation— is expected to have global repercussions.
In 2009, Pfizer became the first pharmaceutical company to earn AAHRPP accreditation for its phase I clinical research units, which are located in New Haven, Conn.; and Brussels, Belgium. The current accreditation applies to all of Pfizer’s phase 2 through 4 clinical trials.
“AAHRPP accreditation affirms that Pfizer provides a higher level of protection for research participants regardless of where they live or the type of trial involved,” said Marjorie A. Speers, Ph.D., AAHRPP president and CEO.
“Thousands of Pfizer researchers worldwide are conducting research in accordance with the ‘gold standard’ for quality and ethics,” Speers added. “That raises the bar and sets an example for other sponsors to follow.”
AAHRPP accreditation is available to U.S. and international organizations that conduct biomedical, behavioral or social sciences research involving human participants. To date, AAHRPP has accredited organizations in 46 states, Canada, China, India, Korea, Singapore and Taiwan.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.